



## Intellia Therapeutics to Present at March Healthcare Investor Conferences

February 28, 2018

CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate at the following upcoming healthcare conferences in March:

### **Tuesday, March 13, 2018**

#### **Barclays Capital Global Healthcare Conference**

Who: John Leonard, M.D., Chief Executive Officer and President

Location: Miami, Florida

Presentation Time: 3:50pm EST

### **Tuesday, March 20, 2018**

#### **Morgan Stanley Healthcare Corporate Access Day**

Who: Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences

Location: Boston, Massachusetts

One on one meetings only

### **Wednesday, March 21, 2018**

#### **Oppenheimer & Co. 28<sup>th</sup> Annual Healthcare Conference**

Who: Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences

Location: New York, New York

Presentation Time: 1:35pm EST

A live webcast of Intellia's presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at [www.intelliatx.com](http://www.intelliatx.com). To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia's website for 14 days following each conference.

### **About Intellia Therapeutics**

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at [intelliatx.com](http://intelliatx.com); Follow us on Twitter @intelliatweets.

### **Investor Contact:**

Lindsey Trickett

Vice President, Investor Relations

+1 857-285-6211

[lindsey.trickett@intelliatx.com](mailto:lindsey.trickett@intelliatx.com)

### **Media Contact:**

Jennifer Mound Smoter

Senior Vice President, External Affairs & Communications

+1 857-706-1071

[jenn.smoter@intelliatx.com](mailto:jenn.smoter@intelliatx.com)



Source: Intellia Therapeutics, Inc.